LOS ANGELES, Aug 25 (Reuters) - A trial of Amgen Inc's Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results